ATE356117T1 - Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität - Google Patents
Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivitätInfo
- Publication number
- ATE356117T1 ATE356117T1 AT03024911T AT03024911T ATE356117T1 AT E356117 T1 ATE356117 T1 AT E356117T1 AT 03024911 T AT03024911 T AT 03024911T AT 03024911 T AT03024911 T AT 03024911T AT E356117 T1 ATE356117 T1 AT E356117T1
- Authority
- AT
- Austria
- Prior art keywords
- oxy
- urea
- phenyl
- represent
- antitumor activity
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 239000004202 carbamide Substances 0.000 title 2
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1485899 | 1999-01-22 | ||
| JP2669199 | 1999-02-03 | ||
| JP14249399 | 1999-05-21 | ||
| JP25362499 | 1999-09-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE356117T1 true ATE356117T1 (de) | 2007-03-15 |
Family
ID=27456291
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00900841T ATE253051T1 (de) | 1999-01-22 | 2000-01-20 | Chinolinderivate und chinazolinderivate |
| AT03024911T ATE356117T1 (de) | 1999-01-22 | 2000-01-20 | Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00900841T ATE253051T1 (de) | 1999-01-22 | 2000-01-20 | Chinolinderivate und chinazolinderivate |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US6797823B1 (de) |
| EP (2) | EP1384712B1 (de) |
| JP (2) | JP3519368B2 (de) |
| KR (1) | KR100787254B1 (de) |
| CN (1) | CN1183114C (de) |
| AT (2) | ATE253051T1 (de) |
| AU (1) | AU771504B2 (de) |
| BR (1) | BR0007656A (de) |
| CA (1) | CA2361057C (de) |
| DE (2) | DE60033857T2 (de) |
| ES (2) | ES2208261T3 (de) |
| HU (1) | HU230789B1 (de) |
| IL (2) | IL144461A0 (de) |
| NO (1) | NO321295B1 (de) |
| NZ (1) | NZ513006A (de) |
| PL (2) | PL204856B1 (de) |
| TR (1) | TR200102090T2 (de) |
| TW (1) | TWI229667B (de) |
| WO (1) | WO2000043366A1 (de) |
Families Citing this family (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP1140840B1 (de) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren |
| EP2298311B1 (de) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | Omega-carboxyarylsubstituierte-Diphenyl-Harnstoffe als p38-Kinasehemmer |
| IL144461A0 (en) * | 1999-01-22 | 2002-05-23 | Kirin Brewery | Quinoline and quinazoline derivatives and pharmaceutical compositions containing them |
| EP1243582A4 (de) | 1999-12-24 | 2003-06-04 | Kirin Brewery | Chinolin- und chinazolinderivate sowie medikamente, die diese enthalten |
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| GB0029015D0 (en) | 2000-11-28 | 2001-01-10 | Univ London | Medical device |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| EP1382604B1 (de) * | 2001-04-27 | 2005-12-28 | Kirin Beer Kabushiki Kaisha | Chinolinderivate mit einer azolylgruppe und chinazolinderivate |
| CA2454538A1 (en) * | 2001-06-22 | 2003-01-03 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same |
| WO2003008388A1 (en) * | 2001-07-19 | 2003-01-30 | Kirin Beer Kabushiki Kaisha | I-form crystal of n-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}-n'-propylurea and process for producing the same |
| JP4383870B2 (ja) * | 2001-10-17 | 2009-12-16 | 協和発酵キリン株式会社 | 線維芽細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
| EP2292615A1 (de) | 2002-02-01 | 2011-03-09 | AstraZeneca AB | Chinazoline Verbindungen |
| ATE529406T1 (de) | 2002-02-11 | 2011-11-15 | Bayer Healthcare Llc | Aryl-harnstoffe als kinase inhibitoren |
| DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| JPWO2003093238A1 (ja) * | 2002-05-01 | 2005-09-08 | 麒麟麦酒株式会社 | マクロファージコロニー刺激因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体 |
| AU2003243318A1 (en) | 2002-05-29 | 2003-12-19 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
| EP1521747B1 (de) | 2002-07-15 | 2018-09-05 | Symphony Evolution, Inc. | Modulatoren von rezeptor-typ-kinase und anwendungsverfahren |
| WO2004039782A1 (ja) * | 2002-10-29 | 2004-05-13 | Kirin Beer Kabushiki Kaisha | Flt3自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| EP1604665B1 (de) * | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase-hemmer |
| US20040242568A1 (en) | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| JP2007511467A (ja) | 2003-05-14 | 2007-05-10 | タケダ サン ディエゴ インコーポレイテッド | ジペプチジルペプチダーゼインヒビター |
| EP1636585B2 (de) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl-harnstoffe mit kinasehemmender wirkung |
| PL1663978T3 (pl) | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
| MXPA06001601A (es) | 2003-08-13 | 2006-08-25 | Takeda Pharmaceutical | Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa. |
| EP2210607B1 (de) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamid zur Behandlung von Krebs |
| AU2013204031B2 (en) * | 2003-09-26 | 2016-10-27 | Exelixis, Inc. | c-Met modulators and methods of use |
| JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
| US20070270589A1 (en) * | 2003-11-28 | 2007-11-22 | Mitsubishi Pharma Corporation | Quinazoline Derivative and Process for Producing the Same |
| AP2006003619A0 (en) | 2003-12-23 | 2006-06-30 | Pfizer | Novel quinoline derivatives |
| TW200530236A (en) | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| US7838524B2 (en) | 2004-04-30 | 2010-11-23 | Bayer Healthcare Llc | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US8426429B2 (en) | 2004-08-06 | 2013-04-23 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
| US8383637B2 (en) * | 2004-08-06 | 2013-02-26 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
| US8436006B2 (en) * | 2004-08-06 | 2013-05-07 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
| US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
| MX2007006230A (es) * | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
| DE602006017188D1 (de) * | 2005-03-07 | 2010-11-11 | Bayer Schering Pharma Ag | Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs |
| JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| TW200740820A (en) * | 2005-07-05 | 2007-11-01 | Takeda Pharmaceuticals Co | Fused heterocyclic derivatives and use thereof |
| JP5066446B2 (ja) * | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を予測する方法 |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| CN102716490A (zh) * | 2005-09-01 | 2012-10-10 | 卫材R&D管理有限公司 | 药物组合物的崩解性的改善方法 |
| NZ566799A (en) | 2005-09-14 | 2011-04-29 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
| WO2007035629A2 (en) | 2005-09-16 | 2007-03-29 | Takeda Pharmaceutical Company Limited | Process for the preparation of pyrimidinedione derivatives |
| KR101353763B1 (ko) | 2005-11-07 | 2014-01-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 c―kit 키나아제 저해 물질의병용 |
| US20090247576A1 (en) * | 2005-11-22 | 2009-10-01 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
| US7776882B2 (en) * | 2006-02-06 | 2010-08-17 | Baxter Ellen W | 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE) |
| WO2007092854A2 (en) * | 2006-02-06 | 2007-08-16 | Janssen Pharmaceutica N.V. | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) |
| US7932261B2 (en) * | 2006-02-06 | 2011-04-26 | Janssen Pharmaceutica Nv | Macrocycle derivatives useful as inhibitors of β-secretase (BACE) |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| CN104706637A (zh) * | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| US20090203693A1 (en) * | 2006-06-29 | 2009-08-13 | Eisai R & D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
| WO2008016192A2 (en) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
| WO2008020302A2 (en) * | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| JP5368096B2 (ja) | 2006-08-28 | 2013-12-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 未分化型胃癌に対する抗腫瘍剤 |
| WO2008044688A1 (en) * | 2006-10-11 | 2008-04-17 | Daiichi Sankyo Company, Limited | Urea derivative |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| EP2123627B1 (de) * | 2007-01-19 | 2013-11-20 | Ube Industries, Ltd. | Verfahren zur herstellung eines aromatischen amins mit einer aralkyloxy- oder heteroaralkyloxygruppe |
| WO2008093855A1 (ja) * | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| US8557853B2 (en) * | 2007-02-09 | 2013-10-15 | Allergan, Inc. | Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents |
| JP5352476B2 (ja) * | 2007-06-05 | 2013-11-27 | 武田薬品工業株式会社 | キナーゼ阻害剤としての二環式複素環化合物 |
| JP5270553B2 (ja) * | 2007-08-23 | 2013-08-21 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| CA2704000C (en) | 2007-11-09 | 2016-12-13 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| NZ586418A (en) * | 2007-12-19 | 2012-09-28 | Cancer Rec Tech Ltd | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| WO2009089851A1 (en) * | 2008-01-17 | 2009-07-23 | Bayer Schering Pharma Aktiengesellschaft | Sulphoximine-substituted quinazoline derivatives as immunomodulators, their preparation and use as medicaments |
| WO2009097278A1 (en) * | 2008-01-28 | 2009-08-06 | Janssen Pharmaceutica N.V. | 6-SUBSTITUTED-THIO-2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) |
| ES2397682T3 (es) * | 2008-01-29 | 2013-03-08 | Janssen Pharmaceutica Nv | Derivados de 2-amino-quinolina útiles como inhibidores de la beta-secretasa (BACE) |
| WO2009096377A1 (ja) * | 2008-01-29 | 2009-08-06 | Eisai R & D Management Co., Ltd. | 血管阻害物質とタキサンとの併用 |
| AU2009226136B2 (en) | 2008-03-17 | 2013-08-15 | Ambit Biosciences Corporation | Quinazoline derivatives as RAF kinase modulators and methods of use thereof |
| JP5746015B2 (ja) * | 2008-04-16 | 2015-07-08 | マックス プランク ゲゼルシャフト ツゥアー フェデルゥン デル ヴィッセンシャフテン エー フォー | Axlキナーゼ阻害剤としてのキノリン誘導体 |
| AU2009303602B2 (en) * | 2008-10-14 | 2012-06-14 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
| EP2399921B1 (de) * | 2008-12-01 | 2015-08-12 | Takeda Pharmaceutical Company Limited | Heterocyclische verbindung und deren verwendung |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| TW201920110A (zh) | 2009-01-16 | 2019-06-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
| EP2408300B1 (de) * | 2009-03-21 | 2016-05-11 | Sunshine Lake Pharma Co., Ltd. | Aminoesterderivate, salze daraus und verfahren zu ihrer verwendung |
| WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
| CN101671301B (zh) * | 2009-05-05 | 2014-02-26 | 江苏省药物研究所有限公司 | 杂环取代的二苯脲类衍生物及其用途 |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| CA2771403C (en) | 2009-08-19 | 2015-02-24 | Eisai R&D Management Co. Ltd. | Quinoline derivative-containing pharmaceutical composition |
| CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
| EP2594566A4 (de) | 2010-07-16 | 2014-10-01 | Kyowa Hakko Kirin Co Ltd | Mit stickstoff angereichertes aromatisches heterocyclisches ringderivat |
| TW201309650A (zh) * | 2011-02-10 | 2013-03-01 | 艾克塞里克斯公司 | 製造喹啉化合物之方法及包含該化合物之醫藥組合物 |
| AU2012246490B2 (en) | 2011-04-18 | 2016-08-04 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| CN102311395B (zh) * | 2011-07-05 | 2014-04-16 | 张爱华 | 喹唑啉环取代的二苯脲类衍生物及其用途 |
| CN102432595B (zh) * | 2011-09-14 | 2013-09-25 | 湖南有色凯铂生物药业有限公司 | N-吲哚-1-酰胺类化合物及作为抗癌药物的应用 |
| CN102408418A (zh) * | 2011-10-21 | 2012-04-11 | 武汉迈德森医药科技有限公司 | Tivozanib酸性盐及其制备方法和晶型 |
| EA023521B1 (ru) | 2011-11-14 | 2016-06-30 | Сефалон, Инк. | ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ |
| CN102603718B (zh) * | 2012-02-08 | 2014-01-29 | 武汉凯斯瑞科技有限公司 | 西地尼布的合成方法 |
| EP2626073A1 (de) | 2012-02-13 | 2013-08-14 | Harmonic Pharma | Verbindung zur Verwendung zur Prävention bzw. Behandlung einer neurogenerativen Erkrankung oder einer Erkrankung mit Phosphodiesterase (PDE4) -4-Aktivierung |
| JPWO2014098176A1 (ja) | 2012-12-21 | 2017-01-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
| US9353122B2 (en) | 2013-02-15 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9695184B2 (en) | 2013-02-15 | 2017-07-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| CA2912219C (en) | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| EP3187491A4 (de) | 2014-08-28 | 2018-08-01 | Eisai R&D Management Co., Ltd. | Hochreines chinolinderivat und verfahren zur herstellung davon |
| US20180028662A1 (en) | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
| KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
| CN108135894B (zh) | 2015-08-20 | 2021-02-19 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| US20190112317A1 (en) | 2015-10-05 | 2019-04-18 | The Trustees Of Columbia University In The City Of New York | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
| CN106496116A (zh) * | 2016-10-21 | 2017-03-15 | 沈阳药科大学 | 含双芳基脲结构的喹啉类化合物及其用途 |
| WO2018102455A1 (en) | 2016-12-01 | 2018-06-07 | Ignyta, Inc. | Methods for the treatment of cancer |
| CN108239067A (zh) * | 2016-12-27 | 2018-07-03 | 沈阳药科大学 | 喹唑啉酮类衍生物及其制备方法和用途 |
| CN110072528B (zh) | 2017-02-08 | 2022-04-26 | 卫材R&D管理有限公司 | 治疗肿瘤的药物组合物 |
| WO2018212202A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| CN109824587A (zh) * | 2017-11-23 | 2019-05-31 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂xjf007及其中间体的制备方法 |
| CN109553581B (zh) * | 2018-09-25 | 2022-01-25 | 广州六顺生物科技股份有限公司 | 取代脲化合物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
| CN111303024B (zh) * | 2018-12-12 | 2023-03-28 | 安徽中科拓苒药物科学研究有限公司 | 一种喹啉结构的pan-KIT激酶抑制剂及其用途 |
| JP2020100598A (ja) | 2018-12-25 | 2020-07-02 | 公益財団法人応用生化学研究所 | レンバチニブ誘導体、並びにそれを用いた医薬研究用組成物及び腫瘍治療剤 |
| AU2020271855B2 (en) | 2019-04-12 | 2025-11-27 | National Health Research Institutes | Heterocyclic compounds as kinase inhibitors for therapeutic uses |
| WO2021144360A1 (en) | 2020-01-17 | 2021-07-22 | F. Hoffmann-La Roche Ag | Small molecule csf-1r inhibitors in therapeutic and cosmetic uses |
| CN113620873B (zh) * | 2020-05-07 | 2023-12-08 | 沈阳药科大学 | 含锌结合基以及喹啉骨架的化合物的制备方法和用途 |
| CN116763787A (zh) * | 2022-03-08 | 2023-09-19 | 安徽中科拓苒药物科学研究有限公司 | 喹啉类化合物的新用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| JP2783722B2 (ja) * | 1991-07-12 | 1998-08-06 | 麒麟麦酒株式会社 | スピカマイシン誘導体およびそれを含む抗腫瘍剤 |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| WO1996009264A1 (fr) * | 1994-09-20 | 1996-03-28 | Sumitomo Metal Industries, Ltd. | Composition de porcelaine dielectrique et son procede de production |
| DE69622183D1 (de) * | 1995-11-07 | 2002-08-08 | Kirin Brewery | Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen |
| JP4194678B2 (ja) | 1997-11-28 | 2008-12-10 | キリンファーマ株式会社 | キノリン誘導体およびそれを含む医薬組成物 |
| IL144461A0 (en) * | 1999-01-22 | 2002-05-23 | Kirin Brewery | Quinoline and quinazoline derivatives and pharmaceutical compositions containing them |
| EP1243582A4 (de) * | 1999-12-24 | 2003-06-04 | Kirin Brewery | Chinolin- und chinazolinderivate sowie medikamente, die diese enthalten |
| EP1382604B1 (de) * | 2001-04-27 | 2005-12-28 | Kirin Beer Kabushiki Kaisha | Chinolinderivate mit einer azolylgruppe und chinazolinderivate |
| JP4383870B2 (ja) * | 2001-10-17 | 2009-12-16 | 協和発酵キリン株式会社 | 線維芽細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
| JPWO2003093238A1 (ja) * | 2002-05-01 | 2005-09-08 | 麒麟麦酒株式会社 | マクロファージコロニー刺激因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体 |
| DE60316590T2 (de) * | 2002-10-21 | 2008-06-19 | Kirin Beer K.K. | N-(2-CHLOR-4-((6,7-DIMETHOXY-4-CHINOLYL)OXYÜPHENYLü-N'-(5-METHYL-3-ISOXAZOLYL)HARNSTOFFSALZIN KRISTALLINER FORM |
| WO2004039782A1 (ja) * | 2002-10-29 | 2004-05-13 | Kirin Beer Kabushiki Kaisha | Flt3自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
| US20040229676A1 (en) * | 2003-04-28 | 2004-11-18 | Gerald Duhamel | Method of playing a game of chance |
-
2000
- 2000-01-20 IL IL14446100A patent/IL144461A0/xx active IP Right Grant
- 2000-01-20 HU HU0105133A patent/HU230789B1/hu unknown
- 2000-01-20 EP EP03024911A patent/EP1384712B1/de not_active Expired - Lifetime
- 2000-01-20 DE DE60033857T patent/DE60033857T2/de not_active Expired - Lifetime
- 2000-01-20 AT AT00900841T patent/ATE253051T1/de not_active IP Right Cessation
- 2000-01-20 JP JP2000594782A patent/JP3519368B2/ja not_active Expired - Fee Related
- 2000-01-20 ES ES00900841T patent/ES2208261T3/es not_active Expired - Lifetime
- 2000-01-20 BR BR0007656-2A patent/BR0007656A/pt active Search and Examination
- 2000-01-20 DE DE60006216T patent/DE60006216T2/de not_active Expired - Lifetime
- 2000-01-20 CN CNB008054282A patent/CN1183114C/zh not_active Expired - Fee Related
- 2000-01-20 EP EP00900841A patent/EP1153920B1/de not_active Expired - Lifetime
- 2000-01-20 TR TR2001/02090T patent/TR200102090T2/xx unknown
- 2000-01-20 KR KR1020017009144A patent/KR100787254B1/ko not_active Expired - Fee Related
- 2000-01-20 US US09/889,858 patent/US6797823B1/en not_active Expired - Fee Related
- 2000-01-20 CA CA2361057A patent/CA2361057C/en not_active Expired - Fee Related
- 2000-01-20 NZ NZ513006A patent/NZ513006A/en not_active IP Right Cessation
- 2000-01-20 PL PL349036A patent/PL204856B1/pl not_active IP Right Cessation
- 2000-01-20 AU AU30748/00A patent/AU771504B2/en not_active Ceased
- 2000-01-20 WO PCT/JP2000/000255 patent/WO2000043366A1/ja not_active Ceased
- 2000-01-20 ES ES03024911T patent/ES2281591T3/es not_active Expired - Lifetime
- 2000-01-20 AT AT03024911T patent/ATE356117T1/de not_active IP Right Cessation
- 2000-01-20 PL PL388667A patent/PL206627B1/pl not_active IP Right Cessation
- 2000-01-21 TW TW089100998A patent/TWI229667B/zh not_active IP Right Cessation
-
2001
- 2001-05-29 NO NO20012617A patent/NO321295B1/no not_active IP Right Cessation
- 2001-07-19 IL IL144461A patent/IL144461A/en not_active IP Right Cessation
-
2003
- 2003-05-06 JP JP2003128216A patent/JP2003286263A/ja not_active Withdrawn
-
2004
- 2004-05-10 US US10/842,009 patent/US7169789B2/en not_active Expired - Fee Related
-
2006
- 2006-09-26 US US11/526,739 patent/US20070027318A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60033857D1 (de) | Derivate des N-((Chinolinyl)oxy)-phenyl)-Harnstoffs und des N-((Chinazolinyl)oxy)-phenyl)-Harnstoffs mit Antitumor Aktivität | |
| BRPI0209216B8 (pt) | derivados de quinolina e de quinazolina, composições farmacêuticas compreendendo os mesmos e seus usos | |
| ATE180468T1 (de) | Anthranilsäure derivate | |
| DK0622361T3 (da) | Heterocykliske forbindelser som bradykininantagonister | |
| DK0918776T3 (da) | Totalsyntese af antitumor acylfulvener | |
| AU2492500A (en) | Aspartic protease inhibitors, compositions, and associated therapeutic methods | |
| ID23954A (id) | Tetrahidrogama-karbolin | |
| DK0784055T3 (da) | Pyrimidinylpyrazolderivater | |
| DK1454903T3 (da) | Thiadiazolinderivater til behandling af cancer | |
| IL160874A0 (en) | 4-imidazolin-2-one derivatives | |
| DE60016384D1 (de) | Chondrogonese promotoren und indolin-2-on derivate | |
| IL153682A0 (en) | Variolin derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
| DE69702775D1 (de) | Chinolinonderivate und diese enthaltende antiallergische Zusammensetzungen | |
| ES2155655T3 (es) | Compuestos de benzotiofeno, usos y formulaciones de los mismos. | |
| IL159792A0 (en) | Variolin derivatives and pharmaceutical compositions containing the same | |
| EP1112998A4 (de) | Aminderivate | |
| EP1251129A4 (de) | Pyrimidinderivate mit antitumor-wirkung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |